Advancing Knowledge on Sickle Cell Disease and Thrombocytopenia-Eliciting Diseases
The Department of Pathology at University Hospitals has long been at the forefront of care and research for sickle cell disease (SCD). Through its apheresis services, the department has played a central role in both acute and chronic patient care. In close partnership with other institutions, University Hospitals has also contributed to clinical trials aimed at improving outcomes for individuals living with SCD. Ongoing leadership by Transfusion Medicine faculty, working collaboratively with sickle cell specialists, reflects a longstanding institutional commitment to advancing care through research and innovation.
Transfusion Medicine and Advanced Cell‑Based Therapies
With the emergence of state‑of‑the‑art gene‑editing and cell‑based therapies, University Hospitals continues to expand treatment opportunities for patients with sickle cell disease. Transfusion Medicine faculty provide expert oversight of hematopoietic progenitor cell collections performed by apheresis for the manufacture of these advanced therapies, helping to ensure quality, safety and access for patients who may benefit from potentially curative approaches.
This expertise positions the Department of Pathology as a key contributor to the responsible integration of next‑generation cellular therapies into clinical care.
Pathologic Mechanisms and Management of Thrombocytopenia‑Eliciting Diseases
In parallel, University Hospitals researchers have pioneered new approaches to understanding the pathologic mechanisms underlying thrombocytopenia‑eliciting diseases, including immune‑mediated thrombotic thrombocytopenic purpura. This work has improved disease recognition and supported timely initiation of apheresis therapy, enabling faster intervention and improved patient outcomes.
By combining diagnostic insight, translational research and clinical expertise, UH Pathology continues to shape best practices in the management of severe platelet disorders.